Alitretinoin
Brand names: Toctino
Alitretinoin is an oral retinoid used for severe chronic hand eczema that has not responded to potent topical corticosteroids.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a vitamin A derivative it binds both retinoic acid and retinoid X receptors, modulating inflammation and keratinocyte activity in the skin.
Prescribing in practice
- It is teratogenic and contraindicated in pregnancy, requiring reliable contraception and pregnancy testing under a pregnancy prevention approach in those who can become pregnant.
- It can raise serum lipids and thyroid-related parameters and affect liver function, so these should be checked before and during treatment.
- Treatment is usually initiated by a specialist and stopped if there is inadequate response after an adequate course.
Monitoring
Monitor lipids, liver and thyroid function, with pregnancy testing where applicable, before and during treatment.
Counselling the patient
- Effective contraception is essential throughout treatment and for the advised period afterwards.
- Report headache with visual disturbance, and expect dryness of skin, lips and eyes.
- Do not donate blood during and after treatment as directed.
Evidence & guidelines
NICE recommends alitretinoin as an option for severe chronic hand eczema refractory to potent topical corticosteroids, supported by the BACH trial.
Reference: NICE TA177 (Alitretinoin for chronic hand eczema, 2009); MHRA Drug Safety Update (Retinoids — Pregnancy Prevention Programme, 2020); BAD Guidelines on hand eczema; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD